ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034

Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com

Close Window

A World Leader in Therapeutics Targeting Misfolded Proteins and Amyloid Diseases

According to the 2013 Alzheimer's Disease International, there are 44.4 million people worldwide with Alzheimer's disease. By 2030, it will rise to 75.6 million people, and 135.5 million in 2050. The total cost of disease will be estimated to be $604 billion.

The global market for Parkinson's disease drug therapies is nearly $3 billion a year and growing. This includes $720 million in the United States. Approximately one percent of the population over the age of 65 is estimated to suffer from Parkinson's disease. In the US about 1.5 million people suffer from this disease. As with Alzheimer's disease, our aging population will give rise to a steadily growing number of people who suffer from Parkinson's disease.

The prevalence of type 2 diabetes in the United States, Europe, and Japan continues to grow at an alarming rate. The type 2 diabetes drug market is expected to reach US $2.5 billion in 2010. ProteoTech's approach to the treatment of this disease allows us to participate in another multi-billion dollar therapeutic market.

There are approximately 3,000 – 5,000 new cases of AL amyloidosis in the USA alone. In certain amyloidosis centers in Europe, approximately 3,000 – 5,000 new cases are reported each year. AL amyloidosis belongs to the orphan disease group which usually leads to market exclusivity and expedited approval for a successful drug demonstrating improved efficacy over standard care.